These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 38470171

  • 1. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
    Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, Lobach I, Martinez AL, Ravichandran S, Alarcon I, Offidani A, Alam MS, Mendes-Bastos P.
    Br J Dermatol; 2024 May 17; 190(6):836-845. PubMed ID: 38470171
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E.
    Lancet; 2023 Mar 04; 401(10378):747-761. PubMed ID: 36746171
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
    Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, Rolleri R, Seegobin S, Baeten D, Ionescu L, Zouboulis CC, Shaw S.
    JAMA Dermatol; 2021 Nov 01; 157(11):1279-1288. PubMed ID: 34406364
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC.
    Lancet; 2024 Jun 08; 403(10443):2504-2519. PubMed ID: 38795716
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A, Menter A, Armstrong A, Ocampo C, Gu Y, Teixeira HD.
    J Drugs Dermatol; 2016 Oct 01; 15(10):1192-1196. PubMed ID: 27741335
    [Abstract] [Full Text] [Related]

  • 10. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
    Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB.
    Br J Dermatol; 2019 Nov 01; 181(5):967-975. PubMed ID: 30916379
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB.
    Ann Intern Med; 2012 Dec 18; 157(12):846-55. PubMed ID: 23247938
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results.
    Morita A, Takahashi H, Ozawa K, Imafuku S, Takekuni N, Takahashi K, Matsuyama T, Okubo Y, Zhao Y, Kitamura S, Takei K, Yokoyama M, Hayashi N, Terui T.
    J Dermatol; 2021 Jan 18; 48(1):3-13. PubMed ID: 33029861
    [Abstract] [Full Text] [Related]

  • 16. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
    Frew JW, Navrazhina K, Grand D, Sullivan-Whalen M, Gilleaudeau P, Garcet S, Ungar J, Krueger JG.
    J Am Acad Dermatol; 2020 Nov 18; 83(5):1341-1348. PubMed ID: 32416208
    [Abstract] [Full Text] [Related]

  • 17. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R, Pozo T, Alfageme F, Díaz Ley B, Osorio GF, Chico R, Vilarrasa E, Silvente C, Ciudad Blanco C, Romaní J, Martorell A, Fernández P, Romero Ferreiro C, Molina Leyva A.
    Actas Dermosifiliogr; 2023 Oct 18; 114(9):755-762. PubMed ID: 37331620
    [Abstract] [Full Text] [Related]

  • 18. Anti-IL17 Secukinumab in hidradenitis suppurativa: A long-term drug survival analysis.
    Roccuzzo G, Repetto F, Giordano S, Sarda C, Comes A, Dapavo P, Quaglino P, Ribero S.
    Exp Dermatol; 2024 Jul 18; 33(7):e15140. PubMed ID: 39032087
    [Abstract] [Full Text] [Related]

  • 19. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
    Esme P, Akoglu G, Dalkıran CD, Caliskan E.
    Dermatol Ther; 2022 Nov 18; 35(11):e15782. PubMed ID: 35996992
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial.
    Ben Abdallah H, Bregnhøj A, Emmanuel T, Ghatnekar G, Johansen C, Iversen L.
    JAMA Dermatol; 2024 Jan 01; 160(1):63-70. PubMed ID: 38055242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.